EU grants Adempas label expansion

The European Commission approves Bayer's (BAYRY) Adempas (riociguat) for two serious types of pulmonary hypertension: chronic -thromboembolic pulmonary hypertension ((CTEPH)) and pulmonary arterial hypertension ((PAH)).

The FDA approved the same indications in October.

The company forecasts peak sales of ~$700M.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs